Targeting the expression of T antigens with selinexor (KPT-330) shows promise for Merkel cell polyomavirus-positive Merkel cell carcinoma treatment

Br J Dermatol. 2021 Jun;184(6):1185-1187. doi: 10.1111/bjd.19801. Epub 2021 Mar 1.

Authors

R Gupta¹, R A Simonette², H Q Doan³, P L Rady², S K Tyring²

Affiliations

¹ Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.
² Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
³ Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 33403670
DOI: 10.1111/bjd.19801

No abstract available

Publication types

Letter

MeSH terms

Antigens, Viral, Tumor
Carcinoma, Merkel Cell* / drug therapy
Humans
Hydrazines
Merkel cell polyomavirus*
Polyomavirus Infections* / drug therapy
Skin Neoplasms* / drug therapy
Triazoles
Tumor Virus Infections*

Substances

Antigens, Viral, Tumor
Hydrazines
Triazoles
selinexor